Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway

Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway

Limb ischemia-reperfusion (I/R) results in both localized tissue harm and injury to distant organs, particularly affecting the kidneys and leading to acute kidney injury. This study evaluates the renoprotective effect of dapagliflozin, a drug frequently prescribed for type 2 diabetes management, in...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiuxiao Zhu, Huiyao Hao, Ya Gao, Na Li, Zibo Liu, Linyi Shu, Qian Wang, Lihui Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Renal Failure
Subjects:
Dapagliflozin
kidney injury
limb ischemia-reperfusion
AMPK/SIRT1
NLRP3
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2495111
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items